Capricor Therapeutics (NASDAQ:CAPR) announced positive long-term data from its on-going HOPE-2 trial demonstrating the potential of its lead candidate, deramiocel, to slow disease progression and preserve upper limb function in patients with Duchenne muscular dystrophy (DMD).
According to Capricor, preservation of skeletal muscle function was shown over three years resulting in a 52% slowing of DMD in patients. Data is being presented as a late breaking poster at the Muscular Dystrophy Association Clinical and Scientific Conference being held from March 16 to 19, 2025, in Dallas.
In a statement, Linda Marban, Ph.D., CEO of Capricor, said, “For patients and families battling DMD, time is muscle. This data showing long-term preservation of skeletal muscle function reinforces that deramiocel is not just slowing the disease—it is rewriting the trajectory of what’s possible for those living with Duchenne.”
“We have continued to see durable, long-term benefits, enabling patients to maintain skeletal muscle and cardiac function when decline was once inevitable,” Dr. Marban added.
